LL-37
Cathelicidin LL-37
LL-37 is associated with antimicrobial and immune claims, but it remains on the restricted side of the current peptide landscape.
Current status
Restricted
Immune-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Unclear
Less visible in reclassification chatter than other peptides in this group.
Primary Use
Immune-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Remains on the restricted list with limited public momentum for change..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when LL-37 status changes
State-specific notes
California
Risk tolerance is especially low for immune peptides.